Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
Weiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I. Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer 2015, 15: 926. PMID: 26597176, PMCID: PMC4657192, DOI: 10.1186/s12885-015-1927-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrain NeoplasmsGerm-Line MutationGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsPrognosisProto-Oncogene Proteins B-rafSurvivorsTelomeraseConceptsMelanoma brain metastasesRecurrent brain metastasesBrain metastasesOverall survivalLong-term melanoma survivorsSingle nucleotide polymorphismsYear old manIndividual patient's tumorGenetic variantsMelanoma patientsMelanoma survivorsPrognostic informationFavorable outcomeNRAS wild typePatient outcomesConclusionsOur dataPatient tumorsImmune functionBrain tumorsExtended survivalOlder menPatientsClinical scenariosGermline analysisTherapeutic interventionsSensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression. Molecular Oncology 2015, 10: 157-165. PMID: 26440707, PMCID: PMC4695284, DOI: 10.1016/j.molonc.2015.09.005.Peer-Reviewed Original ResearchConceptsNew brain metastasesDisease progressionTreatment initiationBrain metastasesDisease activityCtDNA levelsMetastatic melanomaProgression eventsRECIST scoresUseful blood-based biomarkerImmune checkpoint blockadeDisease progression eventsBRAF inhibitor therapyBlood-based biomarkersCell-free DNA assaysCheckpoint blockadeMetastatic diseaseInhibitor therapyTreatment courseLDH levelsPatient managementUseful biomarkerPatientsDroplet digital PCR assaysProgression